Cohort study protocol: Bioresource in Adult Infectious Diseases (BioAID)

Wellcome Open Research

article

Laura J. Shallcross¹  Alexander Mentzer²  Saadia Rahman³  Graham S. Cooke⁴  Shiranee Sriskandan⁴  Mahdad Noursadeghi⁶ 

[1] Institute of Health Informatics, University College London;Wellcome Trust Centre for Human Genetics and the Jenner Institute, University of Oxford;Biomedical Research Centre, Great Ormond Street Hospital for Children;Department of Medicine, Imperial College London;NIHR Health Protection Unit in Antimicrobial Resistance and Healthcare Acquired Infection, Imperial College London;Division of Infection and Immunity;National Insitute of Health Research Biomedical Research Centre

关键词: bioresource;    infectious diseases;    emergency department;    genomics;    diagnostics;    epidemiology;    microbiology;    bacterial infection;   

DOI  :  10.12688/wellcomeopenres.14690.1

学科分类：内科医学

来源: Wellcome

【 摘 要 】

Introduction: Infectious diseases have a major impact on morbidity and mortality in hospital. Microbial diagnosis remains elusive for most cases of suspected infection which impacts on the use of antibiotics. Rapid advances in genomic technologies combined with high-quality phenotypic data have great potential to improve the diagnosis, management and clinical outcomes of infectious diseases.  The aim of the Bioresource in Adult Infectious Diseases (BioAID) is to provide a platform for biomarker discovery, trials and clinical service developments in the field of infectious diseases, by establishing a registry linking clinical phenotype to microbial and biological samples in adult patients who attend hospital with suspected infection.Methods and analysis:4000 individuals have been recruited to the study.  The final cohort will be characterised using descriptive statistics including information on the number of cases that can be linked to biological and microbial samples to support future research studies. Ethical approval and section 251 exemption have been obtained for BioAID researchers to seek deferred consent from patients from whom a RNA specimen has been collected. Samples and meta-data obtained through BioAID will be made available to researchers worldwide following submission of an application form and research protocol.  Conclusions: BioAID will support a range of study designs spanning discovery science, biomarker validation, disease pathogenesis and epidemiological analyses of clinical infection syndromes.

【 授权许可】

CC BY